Resolvins and aliamides: lipid autacoids in ophthalmology – what promise do they hold?

References

• MelmonKLRocklinRERosenkranzRPAutacoids as modulators of the inflammatory and immune responseAm J Med1981711001066166193
   PubMed Web of Science ®Google Scholar
• AloeLLeonALevi-MontalciniRA proposed autacoid mechanism controlling mastocyte behaviourAgents Actions199339C145C1477505999
   PubMedGoogle Scholar
• SerhanCNHongSGronertKResolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signalsJ Exp Med20021961025103712391014
   PubMed Web of Science ®Google Scholar
• SkaperSDBurianiADal TosoRThe ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neuronsProc Natl Acad Sci U S A199693398439898633002
   PubMed Web of Science ®Google Scholar
• Levi-MontalciniRSkaperSDDal TosoRPetrelliLLeonANerve growth factor: from neurotrophin to neurokineTrends Neurosci1996195145208931279
   PubMed Web of Science ®Google Scholar
• Keppel HesselinkJMCostagliolaCFakhryJKopskyDJPalmitoylethanolamide, a natural retinoprotectant: its putative relevance for the treatment of glaucoma and diabetic retinopathyJ Ophthalmol2015201543059626664738
   PubMed Web of Science ®Google Scholar
• TroninoDRussoROstacoloCImprovement of topical palmitoylethanolamide anti-inflammatory activity by pegylated prodrugsMol Pharm2015123369337926289562
   PubMedGoogle Scholar
• No authors listedThe definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007)Ocul Surf20075759217508116
   PubMed Web of Science ®Google Scholar
• MessmerEMThe pathophysiology, diagnosis, and treatment of dry eye diseaseDtsch Arztebl Int2015112718125686388
   PubMed Web of Science ®Google Scholar
• SternMESchaumburgCSPflugfelderSCDry eye as a mucosal autoimmune diseaseInt Rev Immunol201332194123360156
   PubMed Web of Science ®Google Scholar
• LuoLLiDQDoshiAFarleyWCorralesRMPflugfelderSCExperimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surfaceInvest Ophthalmol Vis Sci2004454293423015557435
   PubMed Web of Science ®Google Scholar
• NiederkornJYSternMEPflugfelderSCDesiccating stress induces T cell-mediated Sjögren’s syndrome-like lacrimal keratoconjunctivitisJ Immunol20061763950395716547229
   PubMed Web of Science ®Google Scholar
• LeighNJNelsonJWMellasREAguirreABakerOJExpression of resolvin D1 biosynthetic pathways in salivary epitheliumJ Dent Res20149330030524389810
   PubMed Web of Science ®Google Scholar
• JiRRXuZZStrichartzGSerhanCNEmerging roles of resolvins in the resolution of inflammation and painTrends Neurosci20113459960921963090
   PubMed Web of Science ®Google Scholar
• SerhanCNClishCBBrannonJColganSPChiangNGronertKNovel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processingJ Exp Med20001921197120411034610
   PubMed Web of Science ®Google Scholar
• SerhanCNHongSGronertKResolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signalsJ Exp Med20021961025103712391014
   PubMed Web of Science ®Google Scholar
• SerhanCNLevyBDBrigham and Women’s Hospital, assignee. Use of docosatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthmaUnited States patentUS8569542 B220131029
   Google Scholar
• SmithLConnorKSerhanCNBrigham and Women’s Hospital, assignee. Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularizationUnited States patentUS20100105773 A12010429
   Google Scholar
• RashidSJinYEcoiffierTBarabinoSSchaumbergDADanaMRTopical omega-3 and omega-6 fatty acids for treatment of dry eyeArch Ophthalmol200812621922518268213
   PubMedGoogle Scholar
• AleoDBarabinoSMangiaficoSRolandoMSaitaMGTRB Chemedica International, assignee. Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acidsUnited States patentUS8957110 B22015217
   Google Scholar
• HaworthOLevyBDLipoxins, resolvins and protectins: new leads for the treatment of asthmaExpert Opin Drug Discov200831209122223489078
   PubMed Web of Science ®Google Scholar
• HaasMJNew resolve in inflammation. Science-Business eXchange200813 Available from: http://www.nature.com/scibx/journal/v1/n23/full/scibx.2008.543.htmAccessed September 6, 2016
   Google Scholar
• SchwartzCESavinainenAGjörstrupPResolvin analogs with pharmacokinetic properties suitable for topical administration to treat ocular diseasesInvest Ophthalmol Vis Sci2008493179
   Google Scholar
• CholkarKGilgerBCMitraAKTopical delivery of aqueous micellar resolvin E1 analog (RX-10045)Int J Pharm201649832633426706439
   PubMed Web of Science ®Google Scholar
• ColligrisBPintorJDry eye disease compounds currently under evaluation in clinical trialsAn Real Acad Nacl Farm201480151178
   Google Scholar
• GjorstrupPPflugfelderSPPangelinanSDe PaivaCSResolvins protect against goblet cell loss and reduce corneal epithelial barrier disruption in a murine model of KCSInvest Ophthalmol Vis Sci200849122
   Google Scholar
• LiNHeJGjorstrupPBazanHThe resolvin E1 analogs, RX-10065 and RX-10005 improve tear production and decrease inflammation in a mouse dry eye modelInvest Ophthalmol Vis Sci200849121
   Google Scholar
• PflugfelderSCTsengSCYoshinoKMonroyDFelixCReisBLCorrelation of goblet cell density and mucosal epithelial membrane mucin expression with rose Bengal staining in patients with ocular irritationOphthalmology19971042232359052626
   PubMed Web of Science ®Google Scholar
• de PaivaCSSchwartzCEGjörstrupPPflugfelderSCResolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eyeCornea2012311299130322257864
   PubMed Web of Science ®Google Scholar
• PanZGjorstrupPReinachPResolvins inhibit hypertonicity-induced proinflammatory cytokine release by suppressing MAPK pathway activation in human corneal epithelial cellsInvest Ophthalmol Vis Sci20084912518172084
   PubMedGoogle Scholar
• ZhangFYangHPanZDependence of resolvin-induced increases in corneal epithelial cell migration on EGF receptor transactivationInvest Ophthalmol Vis Sci2010515601560920538990
   PubMed Web of Science ®Google Scholar
• RajasagiNKReddyPBSuryawanshiAGjorstrupPRouseBTApplication of resolvin E1 modulates the severity of HSV-induced corneal immunopathologyInvest Ophthalmol Vis Sci2010513867
   Web of Science ®Google Scholar
• LiNHeJSchwartzCEGjorstrupPBazanHEResolvin E1 improves tear production and decreases inflammation in a dry eye mouse modelJ Ocul Pharmacol Ther20102643143920874497
   PubMed Web of Science ®Google Scholar
• OdusanwoOChinthamaniSMcCallADuffeyMEBakerOJResolvin D1 prevents TNF-α-mediated disruption of salivary epithelial formationAm J Physiol Cell Physiol2012302C1331C134522237406
   PubMed Web of Science ®Google Scholar
• TorricelliAASanthanamAAgrawalVWilsonSEResolvin E1 analog RX-10045 0.1% reduces corneal stromal haze in rabbits when applied topically after PRKMol Vis2014201710171625558174
   PubMed Web of Science ®Google Scholar
• HeJBazanHEOmega-3 fatty acids in dry eye and corneal nerve regeneration after refractive surgeryProstaglandins Leukot Essent Fatty Acids20108231932520202804
   PubMed Web of Science ®Google Scholar
• TianHZhouYElisonJGordonWCGjorstrupPBazanNGResolvin E1 or a resolvin E1 analog inhibits vascular leakage in experimental choroidal neovascularization (CNV)Invest Ophthalmol Vis Sci2008495414
   Google Scholar
• TianHLuYSherwoodAMHongqianDHongSResolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: biosynthesis and mechanisms of anti-inflammatory actionsInvest Ophthalmol Vis Sci2009503613362019443724
   PubMed Web of Science ®Google Scholar
• DasUNLipoxins, resolvins, and protectins in the prevention and treatment of diabetic macular edema and retinopathyNutrition2013291722677359
   PubMed Web of Science ®Google Scholar
• ConnorKMSanGiovanniJPLofqvistCIncreased dietary intake of ω-3 polyunsaturated fatty acids reduces pathological retinal angiogenesisNat Med2007786887317589522
   PubMed Web of Science ®Google Scholar
• DasUNPolyunsaturated fatty acids in pathological retinal angiogenesisCurr Nutr Food Sci2009594111
   Google Scholar
• LeeCHResolvins as new fascinating drug candidates for inflammatory diseasesArch Pharm Res2012353722297737
   PubMed Web of Science ®Google Scholar
• CholkarKTrinhHMVadlapudiADWangZPalDMitraAKInteraction studies of resolvin E1 analog (RX-10045) with efflux transportersJ Ocul Pharmacol Ther20153124825525844889
   PubMed Web of Science ®Google Scholar
• AT Resolve SARLEfficacy and safety of RX-10045 ophthalmic solution for ocular inflammation and pain in cataract surgery Available from: https://clinicaltrials.gov/ct2/show/NCT02329743. NLM identifier: NCT02329743Accessed August 10, 2016
   Google Scholar